termsTerm
Endocrine resistance
When hormone therapy stops controlling a hormone-driven breast cancer, either quickly (primary) or after years (acquired).
Primary resistance: relapse within 2 years of adjuvant ET or progression within 6 months of first-line metastatic ET. Secondary: later relapse or progression. Mechanisms: ESR1 mutations, PI3K/AKT/mTOR activation, cyclin D1/CDK4 amplification, RB loss, FGFR1 amplification, HER2 activation, lineage plasticity. Determines eligibility for INAVO120-type regimens (relapse on/within 12 months of adjuvant ET).
Resistance: what this kind of term is about · animated schematic, not to scale
Category
Resistance